ey0019.10-3 | Clinical Trials | ESPEYB19
J Ware
, JM Allen
, CK Boughton
, ME Wilinska
, S Hartnell
, A Thankamony
, Beaufort C de
, U Schierloh
, E Frohlich-Reiterer
, JK Mader
, TM Kapellen
, B Rami-Merhar
, M Tauschmann
, K Nagl
, SE Hofer
, FM Campbell
, J Yong
, KK Hood
, J Lawton
, S Roze
, J Sibayan
, J Bocchino
, C Kollman
, R Hovorka
, Consortium KidsAP
N Engl J Med. 2022 Jan 20;386(3):209-219. https://pubmed.ncbi.nlm.nih.gov/35045227/Brief Summary: This multicenter, randomized, crossover trial in 74 very young children (age: 1-7 years) with type 1 diabetes (T1D) tested the safety and efficacy of a hybrid closed-loop system for insulin delivery (CamAPS FX) compared with sensor-augmented pump therapy over 16 weeks. The hybrid closed-loop sy...